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of selecting treatment options that may help reduce the risk of
relapse.
PMH53
DIRECT HEALTH CARE COSTS OF SCHIZOPHRENIA IN THE
UNITED STATES: 2002
Wu EQ1, Birnbaum H1, Kessler R2, Beaulieu N1, Daher M1,
Aggarwal J1,Ascher-Svanum H3, Shi L3
1Analysis Group, Inc, Boston, MA, USA; 2Harvard Medical School,
Boston, MA, USA; 3Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: This study quantiﬁes direct health care costs of
schizophrenia patients in the US in 2002, as compared to a
demographically matched control sample. METHODS: Annual
excess health care costs of patients with schizophrenia were esti-
mated for both privately and publicly insured patients. Costs
were estimated using insurance and patient out-of-pocket
payment for patients with at least one schizophrenia diagnosis.
Patients were identiﬁed from two databases: a de-identiﬁed
employer claims database of ~3.0 million beneﬁciaries
(1999–2003) for privately insured patients (n = 1,090), and
Medi-Cal paid claims (2000–2003) for Medicaid patients (n =
14,074). Medicare costs were imputed using Medicare/Medi-Cal
dual eligible patients (n = 6887). Non-schizophrenia controls
were randomly matched to schizophrenia patients in a 3 :1 ratio,
by demographic characteristics (i.e., age, gender, region of resi-
dence). Excess costs were estimated by comparing the costs of
schizophrenia patients to those of controls. Costs were adjusted
to 2002 dollars using the Medical Care CPI. California Medicare
and Medicaid beneﬁciary costs were extrapolated to the U.S.
using published per enrollee costs. Schizophrenia prevalence 
was based on analysis of the National Comorbidity Survey 
Replication (NCS-R) and other epidemiological literature.
RESULTS: The total excess health care costs of the schizophre-
nia population were estimated at about $16.3 billion, with $7.2
billion from outpatient costs, $4.6 billion from drug costs, 
$2.6 billion from hospital inpatient costs, and $1.9 billion from
long term care costs. CONCLUSIONS: A comparison of these
results with previous schizophrenia studies suggests a shift 
from inpatient to outpatient and drug costs in the past decade.
Since 1991, the proportion of total direct health care costs at-
tributable to inpatient services decreased by approximately 
40%. The proportion of costs attributable to drugs and out-
patient costs increased by approximately 28% and 37% res-
pectively. This shift suggests that new effective pharmaceuticals
may lead to potential cost savings through avoiding expensive
hospitalizations.
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DIFFERENTIAL RISKS AND ASSOCIATED COSTS OF
HOSPITALIZATION DURING ANTIPSYCHOTIC TREATMENT IN
MEDICAID PATIENTS WITH SCHIZOPHRENIA
Gianfrancesco F1, Pesa J2
1HECON Associates, Montgomery Village, MD, USA; 2AstraZeneca LP,
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OBJECTIVES: This retrospective claims-based study compared
atypical antipsychotics to typical antipsychotics and to each
other with respect to risk of hospitalization and inpatient costs
among Ohio Medicaid patients with schizophrenia. METHODS:
Relative risks of hospitalization for mental illness between
enrollees with diagnosed schizophrenia treated with any of the
atypical antipsychotics (risperidone, olanzapine, quetiapine,
ziprasidone) or any of the leading traditional antipsychotics
(haloperidol, perphenazine, thioridazine, thiothixene) were
assessed. Cox proportional hazard regression controlled for age,
gender, diagnosis, prior hospitalization and ER use, substance
dependence/abuse, antipsychotic dose, use of other psychotrop-
ics, and other health needs. Differences in length of stay and
inpatient costs (charges) were also assessed. RESULTS: Patients
treated with quetiapine had a 33% lower risk of hospitalization
for mental illness compared with patients treated with typical
antipsychotics (HR 0.672; P = 0.0413), equating to $389 lower
expected annual inpatient charges per patient for quetiapine.
Other pair-wise comparisons of antipsychotic-related hospital-
ization were not statistically signiﬁcant. Risperidone was associ-
ated with signiﬁcantly longer hospital stays than the typicals
(1.78, P = 0.0301), resulting in $303 higher expected annual
inpatient charges per patient. Risperidone also had signiﬁcantly
longer lengths of stay than olanzapine, 1.88 days (P = 0.006),
resulting in higher inpatient charges ($320 annual per patient).
Other differences in length of stay were not signiﬁcant at P <
0.05. CONCLUSIONS: Quetiapine was associated with a 
lower risk of hospitalization for mental illness compared with
typical antipsychotics, resulting in substantially lower inpatient
charges. While risperidone may also have a lower risk of hospi-
talization than the typicals (22% lower, ns P = 0.0932), length
of stay was signiﬁcantly longer, contributing to higher inpatient
charges. Risperidone also had signiﬁcantly longer lengths of stay
than olanzapine with associated higher inpatient costs, and may
also have longer stays than ziprasidone (3.61 days, ns P =
0.0619).
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OBJECTIVES: Patient adherence to medications can be
improved by proper identiﬁcation of patients at risk for non-
adherence. This study aims to classify patients to latent non-
adherence casemix classes varying in degree of adherence, and
to examine the socio-demographic and clinical correlates of class
memberships. METHODS: We used patients (n = 36,195) with
a schizophrenia diagnosis from the 100%-sample Medi-Cal fee-
for-service paid claims data (1999~2003). The date of the ﬁrst
antipsychotic medication (index date) was used to deﬁne a 6-
month pre-index and a 12-month post-index periods. Latent
class analysis was applied to four categorical adherence indica-
tors: a dichotomous variable derived from medication possession
ratio (MPR; cut-off = 0.8); number of treatment attempts (1, 2,
3, 4, > 4), duration of uninterrupted therapy (<30, 30~60,
60~120, 120~240, 240~365, >365 days); and time to ﬁrst
switching of medication (no switching, <30, 30~90, 90~180,
180~365 days). Determinants and consequences of non-adher-
ence were examined by proﬁling each latent class in terms of
covariates and utilization outcomes. RESULTS: Models with up
to ﬁve classes were explored, leading to a ﬁnal selection of three
classes: adherent (prevalence 14.9%), partially adherent (28.1%)
and non-adherent (57.0%) based on the smallest classiﬁcation
error (2.14%). Non-adherent class was associated with minor-
ity ethnicity, more suicide attempts, more hospitalizations and
inpatient rehabilitations than other classes. Partially adherent
class displayed higher outpatient care use, higher depot antipsy-
chotic drugs, and higher rate of polypharmacy. Adherent class
displayed the exact opposite characteristics as non-adherent
class. Total costs in the 12-month follow-up period were $9,370
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(adherent), $12,619 (partially adherent) and $8,675 (non-adher-
ent). The adherent class had a lower average cost than the non-
adherent class in all the cost categories but drug costs were
$1,939 higher (all p-values <0.05). CONCLUSION: Multiple
indicators of adherence to antipsychotic medication capture het-
erogeneity in non-adherence behaviors, which can be modeled
using latent classes, so deﬁne non-adherence casemix.
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STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE
USERS IN MEDICAID
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OBJECTIVE: To determine the relationship between ziprasidone
starting dose and persistence among patients diagnosed with
schizophrenia. METHODS: Adult Medicaid recipients diag-
nosed with schizophrenia and having ziprasidone prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized by starting dosage: low (20–60mg) n = 517; medium
(61mg–119mg) n = 339; and high (120–160mg) n = 341. Per-
sistence was measured using reﬁll patterns, allowing 15-day gaps
between expected reﬁll dates, and compared across starting doses
using Chi-Square tests. Multivariate logistic analysis explored
the simultaneous impact of age, gender, race, and year of treat-
ment initiation in addition to starting dose. RESULTS: Discon-
tinuation rates across the study period (maximum 30 months)
were greater for patients initiated with low (p = 0.001) and
medium dose (p = 0.02) than for high dose patients. Discontin-
uation rates were not statistically different for low and medium
doses. Discontinuation rates at 365, 180, and 90 days were
higher for low dose than high dose (p < 0.05) but not signiﬁ-
cantly different between low and medium or medium and high
doses. These results were similar in the multivariate models.
CONCLUSIONS: Schizophrenia patients started on high doses
of ziprasidone have greater persistence up to 21/2 years than those
who start on low doses.
PMH57
ELECTRONIC MONITORING OF ANTIPSYCHOTIC
ADHERENCE OF OUTPATIENTS WITH SCHIZOPHRENIA AND
SCHIZOAFFECTIVE DISORDER AND ASSOCIATION WITH
SYMPTOMS, QUALITY OF LIFE AND COGNITION
Byerly M1, Thompson A2, Carmody T1, Erwin T1, Bugno R1, Rush J1
1University of Texas Southwestern, Dallas,TX, USA; 2Janssen Medical
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OBJECTIVES: The primary objective compared antipsychotic
non-adherence rates of outpatients with schizophrenia or
schizoaffective disorder as assessed by electronic monitoring vs.
prescriber ratings. Secondary objectives evaluated the relation-
ship between electronically-determined antipsychotic adherence
with (1) various baseline patient characteristics and (2) prospec-
tively assessed symptom severity, quality of life (QoL) and cog-
nition. METHODS: Adult outpatients with schizophrenia or
schizoaffective DSM-IV diagnosis, taking a single oral antipsy-
chotic, and who signed informed consent were eligible. Adher-
ence was measured via electronic-monitored medication vial
caps, prescriber report, patient self-report and research assistant
report, at baseline and monthly for up to six-months, as were
symptom severity (PANSS) and QoL (SQLS, LOF, PSP). Patients
were non-adherent if adherence was <70% for two or more
months during the six-month study. A single cognition assess-
ment (BACS) was performed. RESULTS: Sixty-one patients
(mean age 44.3, b9.1 years, 51% female, illness duration 21.2,
b 10.7 years) were included. Antipsychotic non-adherence detec-
tion was signiﬁcantly higher with electronic monitoring (57%)
vs. prescriber assessment (7%; p < 0.0001, N = 60) and vs.
patient self-assessment (5%; p < 0.0001), but was not different
from research assistant assessment (54%; p < 0.67). While the
total number of patients classiﬁed as adherent and non-adherent
by research assistants and electronic monitoring were similar,
disagreement in assignment occurred in 36% of cases. Poorer
mean adherence was associated with baseline characteristics of
less than high school education (p < 0.0001), non-Caucasian race
(p = 0.001), and more severe symptoms (p = 0.001). Lower mean
adherence rates were also associated with worse mean six-month
symptom (PANSS total; p < 0.002) and lower functioning on one
of three QoL scales (SQLS; p < 0.03) ratings. No relationship
was found between adherence and cognition. CONCLUSION:
In patients with schizophrenia and schizoaffective disorder, non-
adherence is signiﬁcantly underestimated/underreported by pre-
scribers and patients. Results suggest non-adherence with
antipsychotic medication therapy is associated with worse symp-
toms, poorer QoL, less than high school education and non-
Caucasian race.
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OBJECTIVES: To evaluate long-term clinical and economic out-
comes in patients participating in the ongoing Electronic Schiz-
ophrenia Treatment Adherence Registry in Germany, who were
initiated on long-acting injectable risperidone (LAIR). Baseline
and retrospective data will be presented. METHODS: Data are
collected via a secured web-based system for 12 months retro-
spectively and for 2 years prospectively. Data collected include
patient demographics, treatment and hospitalisation history,
reason for initiating new antipsychotic treatment, Clinical
Global Impression—Severity (CGI-S), Global Assessment of
Functioning (GAF) and adverse events. RESULTS: Complete
baseline and retrospective data are available for 744 patients.
Mean (±SD) age is 41.0 years (±12.2), 56% of patients are male,
and 97% have a diagnosis of schizophrenia or schizoaffective
disorder. The mean (±SD) duration of illness at the time of LAIR
initiation is 9.2 (±9.1) years. Eighty-six percent of patients had
a CGI-S score of moderate (30.5%), marked (35.5%) or severe
(20.3%). The mean (±SD) GAF score was 46 (±15). Seventy-two
percent of patients had at least one hospitalisation during the
year before LAIR initiation; 39% patients received oral atypi-
cals, 5% oral conventionals, 15% depot conventionals, and 31%
received different types of antipsychotics simultaneously or
sequentially in the year preceding LAIR initiation. For 10% of
patients, no retrospective medication information was indicated.
The most frequent reasons for LAIR initiation were lack of com-
pliance (37%), insufﬁcient response (27%), and unacceptable
tolerability (16%) with the previous medication(s). Fifty-three
percent of patients started on 25mg/14 days of long-acting
risperidone, 31% on 37.5mg/14 days and 16% on 50mg/14
days. CONCLUSIONS: Patients in this sample demonstrate dis-
tinct symptomatology and impairment in functioning. Despite a
considerable proportion of patients previously treated with novel
